Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Current factor VIII (FVIII) products display a half-life (t(1/2)) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Powell, Jerry S., Josephson, Neil C., Quon, Doris, Ragni, Margaret V., Cheng, Gregory, Li, Ella, Jiang, Haiyan, Li, Lian, Dumont, Jennifer A., Goyal, Jaya, Zhang, Xin, Sommer, Jurg, McCue, Justin, Barbetti, Margaret, Luk, Alvin, Pierce, Glenn F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646317/
https://ncbi.nlm.nih.gov/pubmed/22223821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-09-382846
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados